Group 1 - The company, 3SBio (01530), has entered into a placement agreement with an exclusive placement agent to issue 105 million shares at a price of HKD 29.62 per share, which represents a 6.50% discount to the closing price of HKD 31.68 prior to the agreement [1] - The placement shares will account for approximately 4.14% of the total issued shares after the placement, assuming no changes in the company's issued share capital from the announcement date until completion [1] Group 2 - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion after deducting placement commissions and other related expenses [2] - The company plans to allocate approximately 80% of the net proceeds for research and development expenses, which includes advancing clinical studies for innovative drugs in China and the U.S., supporting indication expansions for commercialized drugs, and building global infrastructure [2] - The remaining 20% of the net proceeds will be used for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]